



26 March 2020

Sydney, Australia

Appointment of New Board Member

Sydney, 26 March 2020: Noxopharm (NOX:ASX) is pleased to announce the appointment of Mr Boris Patkin as a Non-Executive Director to the Company's Board.

Mr Patkin replaces Dr Beata Niechoda who resigned from the Board in 2019 due to family commitments and returns the Board to its previous complement of four directors.

Mr Patkin holds a Bachelor of Science (Industrial Chemistry) and brings to the Board extensive experience in global capital markets through 30 years of experience in financial advisory work, business consulting and stockbroking.

Graham Kelly, Noxopharm CEO and Executive Chairman, said, "Boris joins the Company at an important time in its life as it embarks on a new level in terms of its clinical and commercial activities. Boris adds to the Board's understanding of the investment and capital markets."

About Noxopharm

Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda[®] and is the major shareholder in the non-oncology drug development company, Nyrada Inc. (ASX:NYR).

www.noxopharm.com

Investor & Corporate enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Graham Kelly, CEO and Chairman of Noxopharm, has approved the release of this document to the market.

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.